Immutep presents improving results from INSIGHT-004 trial [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
HealthcareImmutep presents improving results from INSIGHT-004 trialSep. 18, 2020 2:14 AM ET|Immutep Limited (IMMP)Mamta Mayani(NASDAQ:reports further interim dataINSIGHT-004 is evaluating the combination eftilagimod alpha (efti) with avelumab (Bavenico), a human anti-PD-L1 antibody, in 12 patients with different solid tumours, primarily gastrointestinal under collaboration with Merck and Pfizer, which are co-developing and co-commercialising avelumab.INSIGHT-004 (Stratum D) Results Summary41.7% of patients (5 / 12) showed a partial response to the combination therapy (previously 33%).Encouraging early anti-tumour activity signals observed in a variety of cancer indications not typically sensitive to immune checkpoint inhibitor therapy.Interim results show that the combination of efti and avelumab is well tolerated with no dose limiting toxicities.IKF also presented data from the broader INSIGHT trial at ESMO showing thatintratumoral and intraperitoneal administration of efti up to 30
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder [MSNBC.com]MSNBC.com
- Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks [Yahoo! Finance]Yahoo! Finance
- Pfizer's First Gene Therapy Gets Approval for Clotting Disorder [BNN Bloomberg (Canada)]BNN Bloomberg
- UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder [Yahoo! Finance]Yahoo! Finance
- Antibody-Drug Conjugates (ADC) Industry Overview 2024: Market to Exceed $40 Billion by 2029, Driven by Daiichi Sankyo's Enhertu, Roche's Kadcyla, Astellas Pharma, Pfizer's Padcev, & Gilead's Trodelvy [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 1/30/24 - Beat
PFE
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form PX14A6G
- PFE's page on the SEC website